Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221032 · ClinicalTrials.gov registry record · Phase 1
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Not yet
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07221032: Clinical Trial Phase 1 study, sponsored by Medical College of Wisconsin.
NCT07221032 is a Phase 1 study that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221032, a Phase 1 study, has not yet begun recruiting, sponsored by Medical College of Wisconsin.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.
Primary Outcome
This measure is the number of Grade 3 or higher adverse events possibly, probably, or definitely related to the study therapy. Adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded and assessed using the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading systems. Im
Interventions
- BIOLOGICAL FT836 CAR T cells (1 x 10^8 cells per dose)
- BIOLOGICAL FT836 CAR T cells (3 x 108 cells per dose)
- BIOLOGICAL FT836 CAR T cells (up to 9 x 108 cells per dose)
- DRUG Daratumumab 16 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-07 |
| Est. Completion | 2030-03 |
| Phase | Phase 1 |
What is known before NCT07221032 opens enrollment
NCT07221032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 4 interventions - of which FT836 CAR T cells (1 x 10^8 cells per dose) is the first listed.
NCT07221032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07221032 about?
NCT07221032 is a clinical study titled "FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma". This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.
What is the current status of trial NCT07221032?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-07. Estimated completion is 2030-03.
What interventions are being tested in trial NCT07221032?
The interventions under investigation include: FT836 CAR T cells (1 x 10^8 cells per dose) (BIOLOGICAL), FT836 CAR T cells (3 x 108 cells per dose) (BIOLOGICAL), FT836 CAR T cells (up to 9 x 108 cells per dose) (BIOLOGICAL), Daratumumab 16 mg/kg (DRUG).
Who is sponsoring clinical trial NCT07221032?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07221032's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia